User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?

Primary tabs

Orlent, Hans [] Reynaert, Hendrik [] Bourgeois, Stefan [] Dideberg, Vinciane [] Adler, Michael [] Starkel, Peter [UCL] []

Polymorphisms in the region of the interleukin-28B (IL28B) gene have recently been associated with spontaneous and treatment induced clearance of hepatitis C virus infection. The specific mechanisms of how IL28B polymorphisms affect HCV suppression remain unknown. It is a matter of ongoing debate how to incorporate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin. The eventual role of the IL28B genotype in new therapeutic regimes with direct antiviral agents needs to be explored in the ongoing and future clinical studies with these agents.

Document type Article de périodique (Journal article) – Synthèse de littérature – Journal Article, Review
Publication date 2011
Language Anglais
Journal information "Acta Gastro-Enterologica Belgica (Multilingual Edition)" - Vol. 74, no. 2, p. 317-322 (2011)
Peer reviewed yes
Publisher Acta Medica Belgica ((Belgium) Brussels)
issn 0001-5644
Publication status Publié
Affiliations UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service d'hépato-gastro-entérologie
MESH Subject Antiviral Agents - therapeutic use ; DNA - genetics ; Genotype ; Hepacivirus - genetics ; Hepatitis C - drug therapy, genetics, metabolism ; Humans ; Interleukins - genetics, metabolism ; Polymorphism, Genetic
Links
Bibliographic reference Orlent, Hans ; Reynaert, Hendrik ; Bourgeois, Stefan ; Dideberg, Vinciane ; Adler, Michael ; et. al. IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?. In: Acta Gastro-Enterologica Belgica (Multilingual Edition), Vol. 74, no. 2, p. 317-322 (2011)
Permanent URL http://hdl.handle.net/2078.1/96220